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Educating dendritic cells (DC) to become tolerogenic
DC, which promote regulatory IL-10 immune re-
sponses, represents an effective immune evasion
strategy for pathogens. Yersinia pestis virulence
factor LcrV is reported to induce IL-10 production
via interaction with Toll-like receptor (TLR) 2. How-
ever, TLR2/mice are not protected against subcu-
taneous plague infection. Using complementary
in vitro and in vivo approaches and LcrV as a model,
we show that TLR6 associates with TLR2 to induce
tolerogenic DC and regulatory type-1 T cells selec-
tively secreting IL-10. In contrast, TLR1 heterodimer-
izes with TLR2 to promote proinflammatory IL-12p40
cytokine, producing DC and inflammatory T cell
differentiation. LcrV specifically hijacks the TLR2/6
pathway to stimulate IL-10 production, which blocks
host protective inflammatory responses. These re-
sults explain why TLR2 can mediate both pro- and
anti-inflammatory responses and identify TLR6 as
adistinct receptordriving regulatory IL-10 responses.
INTRODUCTION
Dendritic cells (DC) orchestrate the immune response and, in
particular, control T cell activation and polarization via integra-
tion of environmental and microbial signals that determine ex-
pression of costimulatorymolecules and production of cytokines
(reviewed in Kalinski et al., 1999). For instance, differentiation of
proinflammatory IFN-g Th1 cells or anti-inflammatory T regula-
tory type 1 (Tr1) cells producing selectively IL-10 (Groux, 2003)
is linked to the ratio of IL-12 to IL-10 produced by DC (reviewed
in Kalinski et al., 1999). The concept that production of high
levels of IL-10 by DC is not sufficient to induce Tr1 cells is well
illustrated by the observation that DC stimulated by LPS promote
differentiation of Th1 cells even though they secrete high levels of
IL-10 (Pulendran et al., 2001; Re and Strominger, 2004). In con-
trast, TLR2 ligands, such as zymosan, induce high IL-10, pro-
ducing tolerogenic DC that promote differentiation of Tr1 cells350 Cell Host & Microbe 4, 350–361, October 16, 2008 ª2008 Elsev(Dillon et al., 2006). However, intriguingly, other groups have
shown that TLR2 ligands provide a strong inflammatory signal
and promote the development of Th1 cells (Cleveland et al.,
1996). The signals leading to the differentiation of tolerogenic
DC and the induction of Tr1 cells, hence, remain poorly under-
stood. Interestingly, TLR2 is a promiscuous TLR that can form
heterodimers with TLR6 and TLR1 (Takeda et al., 2003; Trianta-
filou et al., 2006) recognizing diacylated or triacylated lipopro-
teins, respectively (Takeda et al., 2002; Takeuchi et al., 2001).
Whether the ability of TLR2 to induce tolerogenic DC and Tr1
cells is determined by the TLR with which it associates remains
to be determined.
An effective evasion strategy by a pathogen would be to target
and educate DC to become tolerogenic and prime regulatory
IL-10 responses that block inflammation, allowing the pathogen
to multiply without restraint. Yersinia pestis, the causative agent
of bubonic plague, must replicate to a high density in the blood
such that fleas can take up sufficient numbers of bacteria and
enable transmission to a new host. Interestingly, induction of
IL-10 by the Yersinia virulence factor LcrV (V-antigen) is reported
to suppress macrophage activation (Overheim et al., 2005; Sing
et al., 2002) and production of inflammatory cytokines (Brubaker,
2003; Nakajima et al., 1995). However, the immune-modulatory
role of LcrV remains controversial for several reasons. LcrV is
a multifunctional virulence factor that is encoded on a 70 kB
virulence plasmid (pYV), which is part of the type III secretion
machinery (T3SS) that allows for the injection of Yersinia outer
proteins (YOPs) directly into the host cell cytosol. These YOPs
inhibit phagocytosis, block NFkB activation, and prevent the
release of chemoattractants by immune cells (Cornelis, 2002).
Thus, it is difficult in that context to determine whether LcrV
has direct immune-modulatory functions. Furthermore, it is
also argued that the synthesis of a lipopolysaccharide (LPS)-lipid
A with poor TLR4-stimulating activity is the dominant strategy
used by Y. pestis to prevent the development of a protective
inflammatory response (Montminy et al., 2006). Finally, in vitro
experiments suggest that LcrV interacts with TLR2 and CD14
to induce IL-10 (Sing et al., 2002). However, TLR2/ mice
show no resistance to plague (Pouliot et al., 2007).
Using complementary approaches, we address the controver-
sial issue as to whether LcrVmay play immune-modulatory func-
tions that contribute to plague pathogenesis. Furthermore, usingier Inc.
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TLR6 Induces Tolerogenic DCLcrV as a model, we establish the molecular basis underlying
TLR-mediated education of tolerogenic DC and the apparently
contradictory pro- and anti-inflammatory functions of TLR2.
Ultimately, our results reveal an unexpected role of TLR6 in
theeducationof tolerogenicDCandYersiniapestispathogenesis.
RESULTS
LcrV Blocks the Development of an Inflammatory
Response during Plague Infection
To evaluate the role of regulatory cytokines in amodel of bubonic
plague, we subcutaneously (s.c.) infected mice deficient for
IL-10, IL-4, and their appropriate littermate controls with
10LD50 plague strain Colorado-92 (CO92). Interestingly, mice
lacking IL-10, but not IL-4, were fully protected from disease.
This protection correlated with a significant reduction in bacterial
burden and splenic IFN-g levels (Figure 1A). Altogether, these
results suggest that IL-10 plays a significant role in plague path-
ogenesis by blocking the development of a Th1 response.
We have previously reported that Y. pestis preferentially target
antigen-presenting cells and, in particular, DC during in vivo
plague infection (Marketon et al., 2005). To test the hypothesis
that LcrV plays a role in the induction of DC with a tolerogenic
phenotype characterized by high levels of IL-10 and low levels
of IL-12p40, we analyzed the cytokines produced by bone mar-
row-derived DC (BMDC) stimulated with bacterial lysate from
wild-type plague (strain KIMD27) or the Dlcrv Y. pestis strain.
The use of bacterial lysates allows us to bypass issues related
to the preparation of recombinant protein. Consistent with the
hypothesis that LcrV displays immune-modulatory properties,
the Dlcrv Y. pestis induced significantly less IL-10 and higher
levels of IL-12p40 than wild-type plague (Figure 1B). To further
assess the critical role of LcrV in Y. pestis-mediated IL-10 pro-
duction and IL-12p40 inhibition, the effects of anti-LcrV and
anti-Yop J, M, D, and Q polyclonal antibodies on DC polarization
were determined. As anticipated, addition of wild-type bacterial
plague lysate with anti-LcrV antibodies, but not anti-Yop poly-
clonal antibodies or control IgGs, blocked IL-10 and increased
IL2-p40 production by BMDC (Figure 1B).
To support the immune-modulatory functions of LcrV in vivo,
the cytokine pattern induced upon plague infection was ana-
lyzed after mice were infected intravenously (i.v.) with 1000 cfu
wild-type plague (Strain KIMD27), Dlcrv Y. pestis, or DyopD Y.
pestis strain. YopD deletion mutant has a defect in Yop translo-
cation but no defect in LcrV secretion in vivo (Williams and Stra-
ley, 1998). As shown in Figure 1C, Dlcrv Y. pestis and DyopD Y.
pestis express comparable levels of YopD and LcrV compared to
wild-type plague, respectively. To analyze the impact of LcrV at
the initial phase of the disease, cytokine responses were ana-
lyzed 12 hr after infection. Importantly, at this time point, wild-
type, Dlcrv Y. pestis, and DyopD Y. pestis had a comparable
bacterial burden (Figure 1C). As anticipated, DyopD Y.pestis
induced levels of IL-10 and IL-12p40 similar to wild-type Yersi-
nia. In contrast, Dlcrv Y. pestis, induced a 3-fold decrease and
2-fold increase in IL-10 and IL-12p40 production, respectively,
resulting in an overall 6-fold decrease in the IL-10/IL-12p40 ratio.
Altogether, these results support the conclusion that the change
in cytokine pattern associated with Dlcrv Y.pestis is not second-
ary to a defect in Yops.Cell HoThese results, in association with the results observed in
IL-10-deficient mice, suggest that the ability of plague to induce
low inflammatory responses cannot be solely attributed to the
synthesis of lipopolysaccharide (LPS)-lipid A with poor toll-like
receptor 4 (TLR4)-stimulating activity. They support the hypoth-
esis that LcrV and IL-10 contribute actively to plague pathogen-
esis by blocking proinflammatory responses.
Recombinant LcrV Induces IL-10 and Suppresses
LPS-Induced IL-12p40 from DC
To directly test the role of LcrV on IL-10 induction and IL-12p40
suppression, we purified recombinant LcrV, PcrV (LcrV homolog),
and an LcrV deletionmutant V10 (Overheimet al., 2005) (Figure 2),
all of which are grown, purified, and treated in the same way. As
shown in Figure S1A, available online, LcrV, but not PcrV, induced
IL-10 in a dose-dependent manner. As previously reported (Over-
heim et al., 2005), the LcrV deletion mutant V10 induced signifi-
cantly lower levels of IL-10 than wild-type LcrV (Figures S1A and
S2). Importantly, LcrV-mediated IL-10 induction was unchanged
in TLR4/ mice (Figure 2A) and blocked upon addition of anti-
bodies against LcrV, but not against YopM or control rabbit IgG
(Figure 2A), eliminating the possible role of endotoxin and other
TLR contaminants. Finally, in agreement with the data presented
in Figures 1B and 1C, addition of LcrV, but not V10 (Figure S1A)
or PcrV, significantly blocked LPS-induced IL-12p40 production
(Figures 2B and S1A). Importantly, this effect was also reversed
by the addition of polyclonal antibodies against LcrV, but not
YopM or rabbit IgG, and was lost in IL-10-deficient mice. Of
note, LcrV displayed similar immune-modulatory properties in
splenic DC and peritoneal macrophages (Figures S2B and S2C).
Altogether, these results (Figures 1, 2, and S1) suggest that
LcrV is both necessary and sufficient to induce DC with a tolero-
genic phenotype, characterized by high levels of IL-10 and low
levels of IL-12p40 production.
TLR6 and CD14 Are Involved in IL-10 Induction and
Contribute to Plague Pathogenesis
Sing et al. (2002) showed that induction of IL-10 by LcrV was
dependent upon TLR2 and CD14. TLR2 can be expressed as a
homodimer, or form receptor, complexes with CD14, TLR1, and
TLR6. To assess the potential role of CD14, TLR1, and TLR6 in
LcrV-mediated immune-modulation and plague pathogenesis,
mice deficient in CD14, TLR6, and TLR1were analyzed (Figure 3).
Interestingly, IL-10 (Figure 3) and IL-12p40 (data not shown) in-
duction by LcrV were abrogated in BMDC derived from TLR2-,
TLR6-, and CD14-deficient mice, suggesting that LcrV signals
through a CD14/TLR2/TLR6 complex. In contrast, LcrV induced
similar levels of IL-10 in TLR1/ mice and wild-type mice (Fig-
ure 3A and data not shown). Loss of IL-10 induction in TLR2-,
TLR6-, and CD14-deficient BMDC was associated with a loss in
the ability of LcrV to block LPS-induced IL-12p40 production.
Of note, as expected, DC fromCD14/mice had reduced levels
of IL-12p40 production in response to LPS, yet they were still
measurable, reaching around 500 pg/ml (Figure 3A).
We next investigated the in vivo role of TLR2, CD14, TLR1, and
TLR6 during plague pathogenesis. Each strain of mouse and its
littermate control were infected subcutaneously with 10LD50
plague (strain CO92). As reported previously (Pouliot et al.,
2007; Reithmeier-Rost et al., 2007), TLR2/ mice thatst & Microbe 4, 350–361, October 16, 2008 ª2008 Elsevier Inc. 351
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TLR6 Induces Tolerogenic DCFigure 1. IL-10 Induction by Y. Pestis LcrV Contributes to Virulence
(A) IL-10/, IL-4/, or littermate controls were infected subcutaneously with 10LD50 (10 cfu) Y. pestis strain CO92. Survival was monitored. *p < 0.002 by
Wilcoxon rank test. At day 3 postinfection, the amount of plague and IFN-g levels in the spleen were measured.
(B) BMDC from C57BL/6 mice were cultured with bacterial lysate from wild-type plague or plague lacking LcrV (Dlcrv Y. pestis). Antibodies against LcrV, Yops,
and control rabbit IgGwere added to cultures, and supernatants weremeasured 24 hr later for levels of IL-10 and IL-12p40. Statistical significancewas performed
using one-way ANOVA. The values are means ± SD from three independent experiments; significant p values are indicated in the figure.
(C) C57BL/6 mice were infected with 1000 cfu wild-type plague strain, plague lacking LcrV (Dlcrv), or wild-type plague lacking YopD (DyopD). Bacterial lysates
fromWT, DlcrV, or DyopD strains were analyzed for expression of LcrV and YopD by western blot. Anti-LcrV was followed by anti-YopD after the membrane was
stripped. At 12 hr postinfection, the spleens were analyzed for bacterial burden and levels of IL-10 and IL-12p40. The ratio of IL-10 to IL-12p40 was calculated as
described in Experimental Procedures. One-way ANOVA was performed. Significant p values are indicated in the figure. The values are means ± SD from ten
individually assayed mice.succumbed had little difference in bacterial load as compared to
littermate controls (Figure 3B). However, TLR2/mice had a sig-
nificant reduction in IL-10 (Figure 3B) and increase in IFN-g
(Figure 3B), suggesting that TLR2may actually be involved in im-
mune-modulation. Even more interesting, mice deficient for ei-
ther CD14 or TLR6 were partially protected from plague infection
compared to their littermate controls (Figure 3C), had decreased
bacteria burden (Figure 3B) as well as barely detectable levels of352 Cell Host & Microbe 4, 350–361, October 16, 2008 ª2008 ElsevieIL-10 (Figure 3B), and had a 3-fold higher amount of IFN-g (Fig-
ure 3B). Consistent with our in vitro data, TLR1 did not play a role
in plague pathogenesis (Figure 3B).
Taken together, these data demonstrate that CD14 and TLR6
contribute to plague pathogenesis by promoting IL-10 produc-
tion and blocking inflammatory responses. Furthermore, these
observations suggest that LcrV interacts with TLR6 and CD14
for induction of IL-10 and suppression of inflammation.r Inc.
Cell Host & Microbe
TLR6 Induces Tolerogenic DCFigure 2. LcrV Induces IL-10 and Sup-
presses LPS-Induced IL-12p40
(A) (Left) Recombinant LcrV, PcrV, or V10 (data not
shown) were added to BMDC cultured from
C57BL/6 mice or TLR4/ mice, and IL-10 levels
were measured by ELISA. The values are means
± SD from three individually assayed mice and
are representative of two independent experi-
ments. (Right) BMDC from wild-type mice were
cultured with PBS, LcrV, PcrV, or V10 (data not
shown) with antibodies against LcrV, YopM, or
Rabbit IgG. Supernatants were assayed by ELISA
after 18 hr for levels of IL-10. One-way ANOVA
was performed, and significant p values are indi-
cated in the figure. The values are means ± SD
from four experiments.
(B) (Left) BMDC from C57BL/6 mice were pulsed
with LPS and, 2 hr later, treated with LcrV or
PcrV. At 24 hr later, supernatants were analyzed
for IL-12p40. (Right) BMDC from wild-type or
IL-10/ mice were pulsed with LPS for 2 hr and
then treated with LcrV or PcrV. IL-12p40 was
measured by ELISA. The values are means ± SD
from four separate experiments. One-way
ANOVA was performed to determine statistical
significance, and significant p values are indicated
in the figure.TLR Ligands Engaging TLR6 Have the Unique Property
of Promoting the Differentiation of Tolerogenic DC and
Tr1 Cells
To determine whether the ability to educate tolerogenic DC was
a generic or specific property of TLR2/6 ligands, we analyzed
a panel of TLR ligands. As indicated previously, the relative
amount of IL-10 and IL-12p40 produced by DC is thought to
play a critical role in determining T cell polarization (as reviewed
in Kalinski et al., 1999). Unexpectedly, the only TLR ligands ca-
pable of inducing a cytokine pattern similar to LcrV in DC, char-
acterized by an IL-10/IL-12p40 ratioR 0.5, were the diacylated
TLR2/6 ligands FSL1 and Pam2CysK4 (Figure 4A). In contrast,
the triacylated TLR2/1 ligand Pam3CysK4 induced a cytokine
pattern similar to LPS with an IL-10/IL-12p40 ratio of% 0.15. In-
terestingly, the TLR2/TLR6 ligand FSL1, similarly to LcrV (Figures
1B and S1B), also inhibited LPS-mediated IL-12p40 production
(Figure S1B), whereas the TLR2/TLR1 ligand Pam3CysK4
increased it (Figure S1B), as previously reported (Hirata et al.,
2008). Other ligands, which induced even higher amounts of
IL-10, were zymosan (which also activates Dectin-1 signaling
[Dillon et al., 2006]) and poly I/C. However, these ligands also
induced high levels of IL-12p40 with an IL-10/IL-12p40 ratio
ofz 0.2 (Figure 4A, right).
To determine whether the cytokine pattern expressed by DC in
Figure 4A was associated with predicted CD4 T cell polarization,
we analyzed the cytokine pattern of ova-specific CD4 T cells
upon immunization with OVA323–339 peptide in association
with LcrV, control PcrV, TLR2/6 (FSL-1), and 2/1 ligands (Pam3-
CysK4) (Figure 4B). Alhydrogel (Li et al., 2007) or incomplete
Freund adjuvant (Gavin et al., 2006) were used as primary adju-
vants because their effects areMyD88 independent. As shown in
Figure 4B, adjuvant alone promoted differentiation of Ag-specific
T cells, producing significant levels of IFN-g and low levels of
IL-10 (Figure 4B). Control PcrV (Figure 4B) and V10 (data notCell Hoshown) did not alter the CD4 T cell cytokine pattern observed
with alhydrogel. Importantly, as anticipated by the DC cytokine
pattern observed in Figure 4A, LcrV and FSL1 induced the differ-
entiation of Ag-specific T cells, producing high levels of IL-10 and
low levels of IFN-g (Figure 4B). Importantly, no IL-4 production
could be detected (data not shown). In contrast, mice immunized
with the TLR2/1 ligand Pam3CysK4 (Figure 4B) and TLR ligands
such as poly I/C (data not shown) induced Ag-specific T cells,
producing high levels of IFN-g and no IL-10. These results could
be reproduced using IFA instead of alhydrogel as a primary ad-
juvant (data not shown). To further confirm that LcrV and TLR2/6
ligands induced T cells with a Tr1 phenotype, i.e., T cells produc-
ing IL-10 in absence of IL-4 and inflammatory cytokines, we
performed intracellular flow cytometry with anti-IL-10 antibodies
in combination with anti-IL4, anti-IFN-g, or anti-IL-17 antibodies
(Figure 4C). As anticipated, immunization with OVA323–339 and
incomplete Freunds adjuvant in association with LcrV and FSL1,
but not PcrV, induced in vivo differentiation of OVA-specific
T cells with a Tr1 phenotype. The induction of typical Tr1 cells
was further supported by the finding that LcrV stimulation,
whether in vitro or in vivo, was never associated with foxp3
expression in T cells (data not shown).
Altogether, these results suggest that TLR2/6 ligands have the
unique property of educating DC to become tolerogenic DC that
produce high levels of IL-10 and promote the differentiation of
Tr1 cells. In contrast, TLR2/1 ligands educate DC to produce
high levels of IL-12p40 and low levels of IL-10, hence, promoting
the differentiation of Th1 cells.
LcrV and TLR2/6 Ligands Redirect Anti-Listeria
Inflammatory Th1 Responses to Regulatory
Tr1 Responses
In order to evaluate whether TLR2/6 ligands could suppress Th1
immunity to microbial infection, we studied the impact of LcrVst & Microbe 4, 350–361, October 16, 2008 ª2008 Elsevier Inc. 353
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TLR6 Induces Tolerogenic DCFigure 3. TLR6 Is Necessary for Virulence and IL-10 Production by Plague
(A) BMDC from TLR2/, CD14/, TLR1/, TLR6/, and C57BL/6 mice were incubated with LcrV or PcrV (left) or pulsed with LPS (right) and then treated 2 hr
later with LcrV or PcrV. The values are means ± SD from five separate experiments, and significant p values are indicated in the figure.
(B) TLR2/, CD14/, TLR1/, TLR6/, and the littermate controls for each strain were infected subcutaneously with 10LD50 (10 cfu) plague strain CO92. At
day 3, postinfection bacterial counts from spleen (left) and levels of IL-10 (center) and IFN-g (right) were determined from splenic supernatants. The values are
means ± SD from five individually assayed mice and are representative of three separate experiments. For (A) and (B), statistical significance was determined
using one-way ANOVA, and significant p values are indicated in the figure.
(C) Survival curve of knockout and littermate control mice infected as described in (B). The data are representative of two experiments with five to ten mice/group
for each experiment, and statistical significance was determined using Wilcoxon log rank test. *p < 0.05.and FSL1 on anti-Listeria responses. PcrV and V10 served as
a control for LcrV and the TLR2/1 ligand, Pam3CysK4, as a con-
trol for FSL1. We chose Listeria monocytogenes for two reasons.
First, clearance and survival of L. monocytogenes infection is
dependent on Th1-mediated immunity. Second, L. monocyto-
genes lack a type III secretion (TTS) system and, thus, allow us
to dissociate the effects of LcrV from TTS.
Survival, bacterial load, and CD4 T cell polarization were mon-
itored in mice treated with recombinant proteins or TLR ligands
after i.v. infection with 1 3 103 CFU (LD50) L. monocytogenes.
As expected,50%of themice treatedwith PBS survived the in-
fection at day 10. Interestingly, LcrV- and FSL1-treatedmice had354 Cell Host & Microbe 4, 350–361, October 16, 2008 ª2008 Elsevivery significant increased mortality. In contrast, V10- (data not
shown), PcrV-, and Pam3CysK4-treated mice behaved similarly
to PBS-treated mice (Figure 5A). Upon necropsy of animals at
day 6, LcrV- and FSL1-treated mice had small spleens similar
in size to thoseofnoninfectedmice, correlatingwithasignificantly
reduced cellular number as compared to PBS-, PcrV-, and
Pam3CysK4-treated mice (Figure 5B). Finally, intracellular cyto-
kine analysis of spleen cells revealed that CD4 T cells in LcrV-
and FSL1-treated mice produced predominantly IL-10, whereas
CD4 T cells of PcrV- and Pam3CysK4-treated mice produced
high levels of IFN-g and little or no IL-10 or IL-4. Importantly, anal-
ysis of mice deficient in IL-10 and IL-4 confirmed, as anticipated,er Inc.
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TLR6 Induces Tolerogenic DCFigure 4. TLR2/6 Ligands Induce High Levels of IL-10 and Can Prime an IL-10-Dominant CD4 T Cell Response
(A) BMDC from C57BL/6 mice were incubated with TLR ligands, LcrV, or PcrV. Supernatants were analyzed for IL-10 (left), IL-12p40 (center), and the ratio of
IL-10:IL-12p40 (right).
(B) C57BL/6 were immunized with OVA323–339 and alhydrogel in association with LcrV, PcrV, FSL1, or Pam3CysK4. At 9 days later, CD4 T cells were isolated
from the lymph nodes and incubated with OVA323–339 and irradiated splenocytes. At 48 hr after stimulation, supernatants were analyzed for IL-10 (left), IFN-g
(center), and the ratio of IL-10:IFN-g (right). The data were analyzed using one-way ANOVA. The values are means ± SD from five individually assayed mice and
are representative of two separate experiments.
(C) Cells were isolated from draining lymph nods of C57BL/6mice 9 days after immunization with OVA and incomplete Freund’s adjuvant in association with LcrV,
PcrV, or FSL1. Cells were restimulated in vitro with OVA and assayed for intracellular IL-4, IL-10, IFN-g, and IL-17 levels. Data is representative of three separate
experiments.Cell Host & Microbe 4, 350–361, October 16, 2008 ª2008 Elsevier Inc. 355
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TLR6 Induces Tolerogenic DCthat the immune-modulatory effects were dependent on IL-10,
but not on IL-4 (Figures S3A and S3B, respectively). In addition,
analysis of the impact of LcrV on L. monocytogenes infection
in TLR6-deficient mice demonstrates that LcrV exerted its
immune-modulatory effects in vivo via TLR6 (Figure S4).
To further assess that LcrV and TLR2/6 ligands could block
bacterial proinflammatory innate signals in a dominant manner,
we confirmed these observations in mice infected with the
gram-negative bacteria Salmonella typhimurium known to
express potent proinflammatory LPS (Figure S5).
Taken together, these data demonstrate that, during bacterial
infection, engagement of TLR2/6 induces a shift fromaprotective
inflammatory Th1 response to a dominant IL-10 regulatory
response, which results in increased bacterial burden and
mortality.
TLR1 and TLR6 Induce Different MAPK Signals in BMDC
The finding that engagement of TLR2/1 promotes IL-12p40 and
leads to inflammation and that TLR2/6 promotes IL-10 and gives
rise to regulatory responses suggests that these ligands engage
Figure 5. LcrV and TLR2/6 Ligand Induce
Immune Suppression In Vivo
C57BL/6 mice were immunized with PBS, LcrV,
PcrV, FSL-1, or Pam3CysK4 and then infected
with 103 cfu L. monocytogenes intravenously.
(A) (Left) Survival of mice was followed for 10 days.
Data are the average of 10 mice/group and repre-
sentative of four experiments. p < 0.001, Wilcoxon
rank test. (Right) Bacterial colonization of the
spleen was assayed at days 1–3. The values are
means ± SD from three separate experiments.
One-way ANOVA was used to compare bacterial
burden at each time point.
(B) Splenic size (left) and cell number (right) were
assayed from five individual mice.
(C) Intracellular levels of IFN-g, IL-10, and IL-4
were assayed in CD4 T cells isolated from the
spleen at day 6 postinfection. Total cell number
was determined by multiplying the percent posi-
tive for intracellular cytokine by the total cell
counts for each mouse. The values are means ±
SD from five individually assayed mice and are
representative of three separate experiments. Sig-
nificant p values are indicated. One-way ANOVA
was used to determine statistical significance for
(B) and (C).
different downstream signals. To exam-
ine the phosphorylation of Mitogen-
activated protein (MAP) kinases c-Jun
N-terminal kinases (JNK), extracellular
signal-regulated kinases (ERK), and p38
MAPK (p38), BMDC were cultured with
increasing doses of LcrV, PcrV, FSL1,
and Pam3CysK4 for 15 min. This time
point was chosen because it was optimal
for all molecules tested (data not shown).
LcrV, FSL1, and Pam3CysK4 all induced
ERKandp38phosphorylation (Figure 6A).
Of note, whereas Pam3CysK4 consis-
tently induced p38 phosphorylation, including at the lowest con-
centration, FSL1 and LcrV failed to induce p38 phosphorylation
in two out of four experiments even though ERK phosphorylation
was observed (data not shown). Presented here is the experi-
ment in which the highest level of p38 phosphorylation was
observed with LcrV and FSL1 (Figure 6A and data not shown).
The most striking signaling property of LcrV and FSL1 (TLR2/6
ligand) that sets them apart from Pam3CysK4 (TLR2/1 ligand)
is their ability to induce consistently, and at low concentrations,
high levels of JNK phosphorylation (30-fold increase at 0.1 mg/ml)
(Figure 6A).
To test the physiological relevance of these findings, BMDC
were treated with LcrV, FSL1, and Pam3CysK4 in the presence
of different concentrations of ERK (PD98059), JNK (SP600125),
and p38 (SB203580) inhibitors or vehicle control (DMSO). After
18 hr, IL-10 and IL-12p40 levels were measured in the superna-
tants. In accordance with our previous results (Figure 4A), Pam3-
CysK4 induced low levels of IL-10 and high levels of IL-12p40,
whereas FSL1 and LcrV produced high levels of IL-10 and rela-
tively low levels of IL-12p40 (Figure 6B). Interestingly, supporting356 Cell Host & Microbe 4, 350–361, October 16, 2008 ª2008 Elsevier Inc.
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TLR6 Induces Tolerogenic DCFigure 6. Engagement of TLR2/6 Leads to Differential MAP Kinase Phosphorylation Patterns
(A) BMDC from C57BL/6 mice were treated with increasing doses of LcrV, PcrV, FSL1, or Pam3CysK4. After 15 min, cell lysates were examined for phosphor-
ylation of MAP kinases. The fold increase was determined using scanning electron densitometry and the equation indicated in the figure.
(B) BMDC were pretreated for 30 min with PD98059 (MEK1/2 inhibitor), SP600125 (JNK inhibitor), SB203580 (P38 inhibitor), or DMSO and then incubated with
LcrV, FSL1, or Pam3CysK4. IL-10 (top panels) and IL-12p40 (bottom panels) were examined 18 hr later by ELISA. The values aremeans ± SD from three individual
experiments. *p < 0.05 as compared to DMSO control.Cell Host & Microbe 4, 350–361, October 16, 2008 ª2008 Elsevier Inc. 357
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ing, loss in IL-12p40 production was selectively observed with
p38 inhibition. Conversely, the pharmacological studies revealed
that only JNK, and to a lesser degree ERK, played a role in LcrV-
and FSL1- mediated IL-10 production. A significant effect of JNK
and ERK inhibition on IL-12p40 induction by FSL1 was also ob-
served. Of note, effects of pharmacological inhibitors on IL-10
and IL-12p40 induction by Pam3CysK4 and LcrV, respectively,
could not be seen because of the very low levels of cytokines
produced.
Altogether, these data suggest that JNK, and to a lesser
degree ERK, activation plays a major role in LcrV and FSL1-
mediated IL-10 induction, whereas p38 plays a major role in
Pam2CysK4-mediated IL-12p40 induction.
The TLR2/6/JNK Pathway Critically Regulates
LcrV- and FSL1-Mediated IL-10 Production
To test the hypothesis that the TLR2/6/JNK pathway plays
a critical role in LcrV-induced IL-10 production, we analyzed
JNK phosphorylation in TLR2-, TLR6- and TLR1-deficient mice
and determined whether DC deficiency in JNK2 lost the capacity
to induce IL-10 in response to LcrV and the TLR2/6 ligand FSL1.
First, we verified that LcrV-induced JNK phosphorylation was
inhibited by addition of anti-LcrV polyclonal blocking antibodies,
but not by anti-YopM polyclonal antibodies or rabbit IgG (Fig-
ure 7A). This result, in conjunction with the data of Figures 1B
and 2, demonstrates that the effects observed are specifically
mediated by LcrV and not by a contaminant.
We next determined whether LcrV- and FSL-mediated JNK
phosphorylation was mediated by TLR2 and TLR6. As shown
in Figure 7B, upon BMDC stimulation with LcrV and FSL1, JNK
phosphorylation was conserved in TLR1-deficient mice but lost
in TLR6-, CD14-, and TLR2-deficient mice. The loss of JNK
phosphorylation parallels the loss of immune-modulation by
LcrV, FSL1, and plague observed in these mutant mice (Figure 3)
and suggests that the TLR2/6/JNK pathway critically regulates
the immune-modulatory properties mediated by LcrV and FSL1.
To further confirm the critical role played by JNK, we analyzed
IL-10 production in WT and JNK2-deficient BMDC upon LcrV
and FSL-1 stimulation. As anticipated, in the absence of JNK2,
LcrV and FSL1 lost the ability to induce IL-10, whereas Pam3-
CysK4 could still induce IL-12p40 (data not shown). These
data confirm the results obtained with the JNK inhibitor
SP600125 shown in Figure 6B.
Altogether, these data demonstrate that the TLR2/6/JNK
pathway plays a critical role in the immune-modulatory proper-
ties of LcrV and FSL1.
DISCUSSION
Our study identifies TLR6 as a critical TLR driving the differenti-
ation of tolerogenic DC and regulatory IL-10 immune responses.
This finding, and our observations that IL-10- and TLR6-deficient
mice are significantly protected from plague infection, sheds
a new light on how pro- and anti-inflammatory immune re-
sponses are determined in vivo by specific innate signals acting
on DC. Furthermore, they provide a molecular basis for LcrV-
mediated immune modulation.358 Cell Host & Microbe 4, 350–361, October 16, 2008 ª2008 ElsevY. pestis has evolved multiple strategies aimed at blocking
immune defense mechanisms, eventually leading to the rapid
death of the host. Immune-modulation by LcrV involving IL-10 in-
duction via interaction with TLR2 (Foligne et al., 2007; Sing et al.,
2005) and CD14 (Sing et al., 2002) was proposed as a potential
mechanism to block the induction of protective inflammatory im-
mune responses against Yersinia. This idea has been challenged
by two groups who have shown no difference between TLR2/
and wild-type mice during subcutaneous plague infection
(Pouliot et al., 2007; Reithmeier-Rost et al., 2007). Goguen and
colleagues (Montminy et al., 2006) proposed as an alternative
explanation that Y. pestis LPS, because of its acylation status,
is aweak TLR4 agonist incapable of driving Th1 responses. How-
ever, if weak TLR4 stimulation were themain reason for defective
inflammatory immune response during plague infection, mice
deficient in the TLR4 coreceptor CD14would have decreased in-
flammatory cytokine production and higher bacterial burden.Our
data show the opposite outcome, whereby CD14/ mice are
able to induce a protective inflammatory response, leading to
Figure 7. TLR2/6 Signaling and IL-10 Induction Are Mediated via
JNK2
(A) BMDC were treated with LcrV or PcrV in the presence of anti-LcrV,
anti-YopM, and anti-Rabbit IgG. After 15 min, the cell lysate was analyzed
by western blot for phosphorylation of JNK. These data are representative of
two different experiments.
(B) BMDC from C57BL/6, TLR2/, TLR6/, TLR1/, and CD14/ were
stimulated with LcrV or PcrV for 15 min and examined for total and phosphor-
ylated JNK by western blot.
(C) BMDC were harvested from wild-type or JNK2/ mice and then treated
with LcrV, PcrV, FSL1, and Pam3CysK4. After 18 hr, supernatants were
analyzed for IL-10 levels by ELISA. The values are means ± SD from three in-
dividually assayed mice and are representative of two separate experiments.
Two-way ANOVA was performed with Bonferroni step-downs; significant p
values are indicated in the figure.ier Inc.
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does not account for the finding that IL-10- and TLR6-deficient
mice mount an inflammatory immune response and are pro-
tected from plague infection. Finally, our studies also indicate
that LcrV is necessary and sufficient tomediate immunemodula-
tory properties. As anticipated,mice infectedwith CO92Y. pestis
strain lacking LcrV (Dlcrv Y. pestis) survived infection up to 1 3
106 cfu (unpublished data). More interestingly, analysis of the
cytokine profile at 24 hr postinfection, when bacterial burden
was comparable in wild-type and Dlcrv Y. pestis, revealed that,
in absence of LcrV, plague was able to induce an inflammatory
immune response. These results were in agreement with in vitro
data showing that bacterial lysates from Dlcrv Y. pestis had no
immune-modulatory properties and that lysates from wild-type
Y. pestis in the presence of blocking anti-LcrV antibodies lost
their ability to induce IL-10 and suppress LPS activation. In vitro
data also indicated that LcrV was sufficient to induce immune
modulation. Intriguingly, LcrV was also able to block induction
of inflammatory immune responses against Listeria monocyto-
genes and Salmonella typhimurium, confirming independently
from plague infection that its immune-modulatory effects were
dominant over other proinflammatory innate signals. The ability
of LcrV to block protective inflammatory immune responses
was lost in mice deficient in TLR6, suggesting that LcrVmediates
its regulatory effects through the engagement of TLR6. Further-
more, in vitro experiments suggest that LcrV actually signals
through a TLR2/TLR6/CD14 complex. In this regard, it is interest-
ing to note that LcrV and TLR2/6 ligands have similar functional
and signal transduction properties. How LcrV engages the
TLR2/TLR6/CD14 complex remains to be determined. Interest-
ingly, mutation of N-terminal residues in LcrV from Y. enterocoli-
tica abrogated IL-10 induction and inhibited TLR2 binding (Sing
et al., 2005), suggesting that the N-terminal portion of LcrV may
bind TLR2. Which portion of LcrV interacts with TLR6 and
CD14 is the object of ongoing studies. Taken together, our obser-
vations strongly suggest that TLR2/TLR6/CD14 engagement by
LcrV plays a critical role in plague pathogenesis via the induction
of IL-10 and the inhibition of protective inflammatory immune
responses. However, our observations do not preclude a role
for decreasedLPSacylation (Montminy et al., 2006) and inhibition
of NFkB activation and phagocytosis by Yops (Cornelis, 2002) in
plague pathogenesis but, rather, suggest that Y. pestis uses re-
dundant strategies to completely block protective inflammatory
and phagocytic immune responses.
Intriguingly, our studies are also in concordance with previous
literature showing no role for TLR2 in plague pathogenesis. This
may be the consequence of TLR2 simultaneously promoting
pro- and anti-inflammatory responses, as previously reported
(Cleveland et al., 1996; Dillon et al., 2006; Jiang et al., 2005; Re
and Strominger, 2004; Revets et al., 2005). TLR2 can be ex-
pressed as a homodimer and a heterodimer in association with
TLR1 or TLR6. Our observations taken as a whole suggest that
TLR6, but not TLR1, induces differentiation of tolerogenic DC
and Tr1 cells. These findings provide an explanation as to why
TLR2 can have pro- and anti-inflammatory properties, and
TLR6-, but not TLR2-deficientmice, are resistant to plague infec-
tion. In that regard, it is interesting to note that, despite the fact
that TLR2-deficient mice show no resistance to plague, they
have lower IL-10 and higher IFN-g than their wild-type littermateCell Hocontrols. We cannot exclude at this point whether TLR6 can be
expressed in the absence of TLR2. Furthermore, TLR6 may
have additional functions that remain unclear. How CD14 comes
into play and whether CD14 alters TLR2 and -6 expression and
signaling remains to be determined. Interestingly, Beutler and
colleagues have reported a mutation within CD14 that can affect
the responses of TLR2/6 ligands (Jiang et al., 2005).
To our surprise, analysis of a comprehensive panel of TLR
ligands revealed that TLR6 was the only TLR able to induce
DC with a tolerogenic phenotype. Of note, some TLR ligands,
such as poly i/c, induced DC producing high levels of IL-10 in
conjunction with high levels of IL-12. Importantly, these DC
promoted the differentiation of Th1, but not Tr1 cells (data not
shown). Future studies will determine whether TLR6 plays a crit-
ical role in intestinal homeostasis. Such a role is supported, but
not demonstrated, by the observation that lactobacillus bacteria
engineered to express LcrV produced high levels of IL-10 in
a TLR2-dependent manner and protected mice from developing
colitis (Foligne et al., 2007).
The opposing functional properties of TLR2/6 and TLR2/1 li-
gands led us to examine whether engagement of TLR1 or TLR6
in association with TLR2 induced different MAPK-signaling path-
ways. ERK activation was induced by all TLR2 ligands and was
critical, depending on the TLR2 ligand, for IL-10 and IL-12p40
production. The key difference between TLR2/6 and TLR2/1
ligands was the ability of the former, but not the latter, to induce
strong levels of JNKphosphorylation. In contrast, TLR2/1 ligands
inducedmore readily p38 phosphorylation.Moreover, p38 inhibi-
tion resulted in loss of TLR2/1 proinflammatory functions,
whereas JNK inhibitionwas associatedwith a loss of IL-10 induc-
tionbyTLR2/6 ligands. The critical role of JNK inTLR2/6 signaling
was further demonstrated by the loss of IL-10 induction in JNK2-
deficient mice. The relative contribution of individual MAPK to
TLR signaling remains a complex issue and may depend on the
nature of the ligand and the effector response.
In this paper, we have identified TLR6 and JNK activation as
critical elements for the generation of tolerogenic DC. These
results also suggest that TLR6 may be a very interesting thera-
peutic target because, in contrast to TLR2 and CD14, it is
uniquely associated with regulatory IL-10 responses. Targeting
TLR6 may be highly relevant in infectious diseases, such as
tuberculosis (Kursar et al., 2007) and disseminated candidiasis
(Netea et al., 2008), where the infectious agents harbor TLR2/6
ligands and increased IL-10 is associated with defective protec-
tive responses. Furthermore, stimulation of TLR6 may constitute
a new therapeutic avenue for chronic inflammatory bowel dis-
ease. In this regard, it is interesting to point out that IL-10-
deficient mice develop spontaneous colitis (Rennick and
Fort, 2000) and that a genetic study identified a link between
TLR6 and colitis (Pierik et al., 2006).
EXPERIMENTAL PROCEDURES
Mice
C57BL/6, IL-10/ (C57BL/6 background n = eight backcrosses), IL-4/
(C57BL/6 background n = eight backcrosses), TLR2/ (n = eight back-
crosses), and CD14/ (n = eight backcrosses) mice were purchased from
Jackson Laboratory (Bar Harbor, ME). TLR1/ and TLR6/ mice were gen-
erously donated by S. Akira. All mice were bred to C57BL/6 mice for one gen-
eration to obtain F1. Heterozygote F1mice were bred with each other to obtainst & Microbe 4, 350–361, October 16, 2008 ª2008 Elsevier Inc. 359
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TLR6 Induces Tolerogenic DCF2 knockouts and littermates. OT2 (C57BL/6 background n = 8). All mice were
maintained at University of Chicago, and all animal experiments were per-
formed in accordance with institutional guidelines following experimental pro-
tocol review and approval by the Institutional Biosafety Committee and the In-
stitutional Animal Care and Use Committee.
Bacterial Strains and Infections
Two strains of plague were used for in vivo studies. Colorado 92 (CO92) is
a fully virulent strain that, when injected subcutaneously, mimics the early
stages of bubonic plague but rapidly enters the blood, causing a septicemic
infection and death. KIMD27, also referred to as KIMD5, is a nonpigmented,
attenuated strain that, when injected intravenously, mimics the septicemic
stage of plague and is lethal. KIMD5 and KIMD27 are used interchangeably
for the same strain in the plague field (Brubaker, 1969; Overheim et al., 2005).
Yersinia pestis CO92 is a clinical isolate routinely used in experimental
models of plague (Davis et al., 1996) and obtained from Dr. Susan Welkos
(United States Army Medical Research Institute of Infectious Disease, Bacte-
riology Division, Fort Detrick, MD). For the bubonic plague model, mice were
challenged by subcutaneous injection with 0.1 ml aliquots of 50 cfu/ml. For
this experiment, Y. pestis CO92 was grown in HIB at 26C overnight. The
plague bacilli were washed and diluted in sterile PBS to the required concen-
tration. Mice were observed for morbidity, mortality, and recovery over
a course of 10–14 days.
LcrV mutant Y. pestis (KIM D27 Dlcrv) has been previously described (Que-
nee et al., 2008).Y. pestisKIMD27 andDlcrvwere grown in heart infusion broth
(HIB; Difco) at 26C overnight, diluted 1:20 in fresh HIB, and grown for an ad-
ditional 3 hr at 26C. Mice were infected by retro-orbital injection with 100 ul of
bacterial suspensions (containing 100 or 1,000 cfu) and observed for 14 days,
and the deaths were recorded. Surviving animals were euthanized at the end of
the observation period.
Protein Expression Purification
LcrV, PcrV, and V10 were prepared as previously described (Overheim et al.,
2005). Lipopolysaccharide (LPS) contamination of purified proteins was
assayed with Limulus amebocyte lysate (QCL-1000, Cambrex, NJ) and deter-
mined to be less than 1 ng/100 mg purified protein. Protein concentrationswere
determined by the bicinchoninic acid assay (Pierce Technology, Rockford, IL).
BMDC Culture and Stimulation
Culture of BMDC has been modified from Inaba et al. (1992) and described
previously (Marketon et al., 2005). The phenotype of BMDC on day 8 before
stimulation is CD11chiCD11b+B220lo ClassIIint, CD80int, CD86int, CD40lo
(data not shown). BMDC were stimulated with TLR ligands (Invivogen San
Diego, CA). For studies using bacterial lysate, bacteria were adjusted to
108 cfu/ml, and 53 106 cfu equivalents were used to stimulate 53 105 BMDC.
Immunization
C57BL/6 mice were immunized subcutaneously with 50 mg OVA peptide 323–
339 (Peptides International, Louisville KY) and 50 mg LcrV, V10, PcrV, FSL-1
(Invivogen) or Pam3CysK4 (Invivogen) emulsified in IFA (Sigma, St. Louis,
MO) or alhydrogel (Sigma) at three sites on the rear flank. On day 8 following
immunization, mice were euthanized, and draining lymph nodes were
harvested.
Cytokine Assays
CD4 T cells from immunized mice were isolated by magnetic sorting from
either spleen or draining lymph nodes. Cells were incubated at 37C in a
humidified atmosphere containing 7.5% CO2 with irradiated splenocytes
(300 RADS) with OVA peptide in RPMI-1640 containing 10% fetal calf serum,
100 U/ml penicillin (Invitrogen, Carlsbad, CA), 100 mg/ml streptomycin (Invitro-
gen), and 53 105 M 2-mercaptoethanol. Supernatants were harvested at 48
and 72 hr and analyzed for cytokine production (IL-10, IL-4, and IFN-g) by
ELISA (BD PharMingen, San Jose CA). For studies using spleen homogenates,
one spleen was homogenized in 1 ml of PBS.
Flow Cytometry
Cells (0.5–1 3 106) were washed and incubated with anti-mouse FcRII/III
(CD16/32 clone 2.4 G2; BD PharMingen) for 15 min at 4C to prevent nonspe-360 Cell Host & Microbe 4, 350–361, October 16, 2008 ª2008 Elsevicific Fc binding. Cells were washed in PBS with 10% BSA (Sigma) and labeled
directly with mAbs specific for lymphocyte surface markers CD80-PE (BD 16-
1OA1), CD86-PE (BDGL1), CD40 PE (BD 3/23), MHC class II (FITC AF6-120.1),
CD11c FITC (BD HL3), CD4 PeCy5 (BD L3T4), and CD11b APC (BD M1/70) at
4C for 15 min. Expression was determined on a FACSCalibur flow cytometer
(BD Biosciences) using CellQuest software (BD Biosciences). Intracellar flow
cytometry was performed using anti-IL-10 APC (eBioscience JES5-16E3),
anti-IL-4 PE (BD 11B11), anti-IFN-g APC (BD XMG1.2), and anti-Foxp3 APC
(eBioscience FJK-16 s) and analyzed as described above.
Intravenous Challenge with Listeria Monocytogenes
L. monocytogenes strain EGD was grown overnight at 37C. Bacteria were
prepared by inoculating 50 ml BHI with 1 ml of the overnight culture and grown
at 37C for 3 hr. The concentration was evaluated by optical density at 600 nm.
Serial dilutions were prepared for use in animals, and the inoculum was
confirmed by plating on BHI plates.
Mice were infected retro-orbitally (RO) with either 1 3 103 or 1 3 105 cfu L.
monocytogenes and treated intraperitoneally for 4 days with 50 mg LcrV, PcrV,
V10, FSL1, Pam3CysK4, or PBS. At 3 days after infection, bacterial loads were
assessed in the spleens of mice. Homogenized spleens were diluted and
plated in triplicate on BHI plates and grown at 37C for 48 hr. Surviving mice
were euthanized on day +6, and spleens were mechanically disrupted and
plated at a density of 5 3 106/well in a 24-well plate. The cells were treated
with brefeldin A for 5 hr, and intracellular levels of IL-10, IL-4, and IFN-g
were assessed by flow cytometry. Parallel cultures were set up and stimulated
with heat-killed L. monocytogenes (107/ml), and supernatants were harvested
and analyzed for cytokine by ELISA.
Cell Signaling
To look at MAPK (JNK, ERK, and P38) phosphorylation, 1–2 3 106 cells were
serum starved and stimulated for the indicated time with LcrV, PcrV, and
different TLR ligands. When used, MAPK inhibitors were added to the cells
30 min prior to stimulation. Cells were lysed for 20 min in ice-cold lysis buffer
containing fresh protease and phosphatase inhibitors (50 mM Tris-Hcl
[pH 7.5]; 150 mM NaCl; 1% Triton X-100; 1 mM EDTA; 1 mM Na3VO4; 1 mM
NaF; and protease inhibitor cocktail tablets). Cellular debris was removed by
centrifugation at 15,000 rpm for 20 min at 4C. Total lysates were subjected
to SDS-PAGE electrophoresis and transferred to PVDF membranes (Biorad).
Proteins were then detected by using the indicated antibodies followed by
HRP-conjugated goat anti-mouse (HRP-GAM) or donkey anti-rabbit (HRP-
DAR) Abs (Jackson Immunoresearch Laboratories) using the enhanced
chemiluminescence (ECL) kit from Amersham Pharmacia Biotech.
Scanning densitometry was performed using the NIH Image J (version 1.1.)
software.
Statistics
One-way and two-way ANOVAs were used when noted in figure legends.
Tests that had an interaction of p < 0.05 were further analyzed using Bonferroni
step-down tests, comparing each group to LcrV. Wilcoxon rank test was used
for analysis of survival.
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